'Part of recovery is awareness': Pandemic casts harsh spotlight on industry-wide lack of diversity in clinical trials
Moderna emerged as an early leader in the race for a vaccine to stop Covid-19 in its tracks. The Cambridge, Massachusetts-based biotech bounded through development of one of the world’s first mRNA vaccines, but in September — when the pandemic was claiming upwards of 700 lives a day in the US — they took a step back.
The company did something not many (if any) biotechs have ever done: At the urging of the US government, they slowed Phase III enrollment to recruit more participants from minority groups.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.